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Glucocorticoids are potent immunosuppressants which work in part by inhibiting cytokine gene transcrip-
tion. We show here that NF-kB, an important regulator of numerous cytokine genes, is functionally inhibited
by the synthetic glucocorticoid dexamethasone (DEX). In transfection experiments, DEX treatment in the
presence of cotransfected glucocorticoid receptor (GR) inhibits NF-kB p65-mediated gene expression and p65
inhibits GR activation of a glucocorticoid response element. Evidence is presented for a direct interaction
between GR and the NF-kB subunits p65 and p50. In addition, we demonstrate that the ability of p65, p50, and
c-rel subunits to bind DNA is inhibited by DEX and GR. In HeLa cells, DEX activation of endogenous GR is
sufficient to block tumor necrosis factor alpha or interleukin 1 activation of NF-kB at the levels of both DNA
binding and transcriptional activation. DEX treatment of HeLa cells also results in a significant loss of nuclear
p65 and a slight increase in cytoplasmic p65. These data reveal a second mechanism by which NF-kB activity
may be regulated by DEX. We also report that RU486 treatment of wild-type GR and DEX treatment of a
transactivation mutant of GR each can significantly inhibit p65 activity. In addition, we found that the zinc
finger domain of GR is necessary for the inhibition of p65. This domain is also required for GR repression of
AP-1. Surprisingly, while both AP-1 and NF-kB can be inhibited by activated GR, synergistic NF-kB/AP-1
activity is largely unaffected. These data suggest that NF-kB, AP-1, and GR interact in a complex regulatory
network to modulate gene expression and that cross-coupling of NF-kB and GR plays an important role in
glucocorticoid-mediated repression of cytokine transcription.
Glucocorticoids have long been used as effective immuno-
suppressive agents in the treatment of conditions involving
T-cell- or cytokine-mediated tissue damage. These steroids
have been shown to block inflammation, suppress immune
system activation, and act as growth-inhibitory agents both in
vivo and in vitro (23). Surprisingly, despite the lengthy history
of the use of glucocorticoids as therapeutic agents, the mech-
anism by which they perform these functions is largely un-
known.
Studies of the effect of glucocorticoid administration on the
immune system have resulted in a number of important obser-
vations. Glucocorticoids induce a rapid redistribution of lym-
phocytes from the circulation to other lymphoid compartments
(23). In addition, glucocorticoids potently suppress lymphocyte
accessory function, the clonal expansion of T lymphocytes, and
the secretion of cytokines (23, 73). Interestingly, cytotoxic T-
lymphocyte clones provided with exogenous interleukin 2
(IL-2) are able to proliferate in response to mitogenic stimu-
lation in the presence of glucocorticoids (28). These data sug-
gest that the block of cytokine secretion plays an important
role in glucocorticoid-mediated immunosuppression. Indeed,
glucocorticoid administration represses the de novo transcrip-
tion of a number of cytokine genes, including those for IL-1,
IL-2, IL-6, granulocyte-macrophage colony-stimulating factor
(GM-CSF), tumor necrosis factor alpha (TNF-a), and gamma
interferon (22, 23, 77).
Glucocorticoids function by binding to specific cytoplasmic
receptors, allowing the complex to translocate into the nucleus.
Glucocorticoid receptors (GR) are members of the steroid
hormone receptor superfamily, all of which contain a homol-
ogous DNA-binding domain and divergent C-terminal ligand-
binding domains (9, 26). Activated GR have been shown to
bind to specific DNA elements, glucocorticoid response ele-
ments (GREs) and negative GREs, resulting in transcriptional
activation and repression, respectively (25, 62, 81). Many cy-
tokine genes have been cloned, and their promoters have been
analyzed. Interestingly, nGRE consensus sequences have not
been identified in these promoters, suggesting that GR inhibit
cytokine gene transcription through a different mechanism.
Recently, a number of workers have described a mechanism
of GR-mediated transcriptional repression involving the phys-
ical interaction of GR and AP-1 (24, 35, 46, 68, 82). This
interaction, termed cross-coupling, results in glucocorticoid-
mediated repression through AP-1-responsive elements. NF-
kB, an activator of a broad class of immune system genes, has
also been shown to cross-couple with other transcription factor
families, including AP-1 (74), SP1 (56), and C/EBPb (75).
Interaction of NF-kB and AP-1 results in the synergistic acti-
vation of both kB and AP-1 response element function, while
interaction of NF-kB and C/EBPb results in the enhancement
of C/EBPb and the repression of kB response element func-
tion. As NF-kB sites have been mapped for a large number of
cytokine promoters and shown to be necessary for stimulation
of cytokine gene transcription (3, 29, 36, 44, 45, 66, 72, 83), this
transcription factor, in addition to AP-1, is an excellent candi-
date as a target for glucocorticoid-mediated repression of cy-
tokine expression.
NF-kB, originally identified and named for its role in the
regulation of immunoglobulin kappa chain gene expression in
B cells (43, 70), is a heterodimer of a 50-kDa subunit (p50;
NFKB1) and a 65-kDa subunit (p65; RelA) (6, 39). These
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subunits, along with the more recently cloned p52 (NFKB2)
and RelB proteins, share homology with the products of the
c-rel oncogene and Drosophila dorsal maternal effect gene (15,
27, 41, 47, 53, 60, 61, 64). The p50 and p52 subunits are derived
from 105- and 100-kDa precursors, respectively, by proteolytic
cleavage. It has been shown both in vitro and in vivo that
NF-kB/Rel proteins can dimerize to produce a number of
different NF-kB-like factors (32, 41, 53, 60, 80). Presynthesized
NF-kB is stored in the cytoplasm bound to the inhibitor, IkB
(4, 5). In addition, NF-kB subunits can be found sequestered in
the cytoplasm by the dimeric association with NF-kB precursor
molecules (48, 59, 63). IkB and NF-kB precursors share do-
mains encoding the so-called ankyrin repeats which have been
shown to play an important role in both blocking NF-kB bind-
ing to DNA and masking the nuclear localization signal (12, 14,
34). A wide variety of stimuli including mitogens, cytokines,
lipopolysaccharide, reactive oxygen intermediates, and viral
infection rapidly induce the dissociation of IkB, allowing
NF-kB to translocate to the nucleus (7, 8, 12, 43, 44, 52, 67, 69).
These inducers lead to the phosphorylation and rapid degra-
dation of IkB (11, 17, 76). Thus, NF-kB is part of a richly
complex regulatory network which plays a critical role in the
rapid induction of cytokines and other immune system genes.
In this study, we demonstrate with transfected cells and with
endogenous GR and NF-kB that activated GR are capable of
blocking the ability of NF-kB to activate gene expression, as
recently described (49, 58). We show that GR can physically
interact with NF-kB subunits and also block their ability to
bind DNA. In addition, we present new data showing that
dexamethasone (DEX) treatment of HeLa cells causes a sig-
nificant reduction in nuclear p65 protein levels. Thus, glu-
cocorticoids are also able to inhibit NF-kB activity by a novel
mechanism involving a block of cytokine-induced nuclear
translocation. In addition, we show that the zinc finger region
of GR is required for the inhibition of NF-kB but that GR-
mediated transactivation cannot entirely account for the re-
pression of NF-kB. Given the role of NF-kB in the processes of
T-cell activation and inflammation, we propose that GR inter-
action with the NF-kB system represents an important mech-
anism for the immunosuppressive properties of glucocorti-
coids.
MATERIALS AND METHODS
Cell culture. COS-7 cells were maintained in Iscove’s Dulbecco’s minimal
essential medium (DMEM), as modified by Iscove with 5 mM glutamine, 7.5%
fetal calf serum (FCS), 100 U of penicillin per ml, and 100 mg of streptomycin per
ml and passaged every 3 days. F9 cells were maintained in the same medium and
passaged every 2 days. Plates for F9 cultures were pretreated with 0.1% gelatin
(Sigma) in phosphate-buffered saline (PBS) to increase cell adhesion. Adherent
HeLa cells were maintained in Eagle’s MEM supplemented with 10% FCS, 100
U of penicillin per ml, and 100 mg of streptomycin per ml and passaged every 3
days. For certain transfection experiments, prior to DEX (Steraloids, Inc.) treat-
ment, the medium was replaced with fresh medium containing charcoal-stripped
FCS (HyClone).
Plasmid construction. Expression vectors encoding fos, jun, and the NF-kB
subunits p50, p65, and c-rel consist of human cDNAs cloned into the pCMV4T
plasmid as described elsewhere (2, 74, 75). pCYGR was constructed (by Y.
Itoh-Lindstrom and J.A.C.) by isolating a 3.0-kb KpnI-XhoI cDNA fragment of
the pRSVhGR plasmid (54) encoding the human GR and cloning it into the
pCMV5 plasmid. pCMV4T and pCMV5 have identical promoters. D77/262GR
was constructed by deleting a BglII fragment from pYCGR. D428/490GR was a
generous gift from Ron Evans, Salk Institute. The NF-kB reporters, 3xMHC
CAT and 3xMHCLUC, consist of three copies of the major histocompatibility
complex (MHC) class I H-2Kb NF-kB site cloned upstream of a minimal fos
promoter chloramphenicol acetyltransferase (CAT) expression vector (63) and
the luciferase reporter construct pGL2-Basic (Promega), respectively. The
3xMHCLUC construct was a generous gift of T. Mitchell, University of Wiscon-
sin. The AP-1 reporter, AP-1CAT, consists of five copies of the collagenase AP-1
site cloned upstream of a TK promoter CAT expression vector (74). The GR
reporter, GRECAT, was cloned as described previously (1).
Transfections, CAT assays, luciferase assays, and protein assays. COS cells
were transfected by the DEAE-dextran method as described elsewhere (38).
DEX was added to a final concentration of 1027 M immediately after the
chloroquine-containing medium was replaced by fresh medium. The plates were
harvested 24 to 48 h later. For CAT assays, the cells were resuspended in 0.1 ml
of 0.25 M Tris (pH 7.4), lysed by four cycles of freeze-thaw, and incubated for 10
min at 708C to inactivate endogenous inhibitors of CAT. For luciferase assays,
plates were incubated with reporter lysis buffer (Promega) and cells were pro-
cessed as recommended by the manufacturer. F9 and HeLa cultures were trans-
fected by the calcium phosphate method as described previously (31). The
DNA-Ca3(PO4)2 solution remained in contact with the cells for 16 h, after which
the plates were washed with PBS and fresh medium was added. For F9 experi-
ments, DEX was added at this time to a final concentration of 1027 M, and the
cells were harvested 18 to 22 h afterwards. HeLa cells were allowed to recover for
4 h after removal of the crystals and then treated with DEX or RU486 (gift of D.
Gallet, Roussel Uclaf) as described above. TNF-a (2 ng/ml) or IL-1 (10 ng/ml)
was then added 20 h later, and the HeLa cultures were harvested an additional
24 h later. Cell extracts were stored at 2208C until assayed. CAT activities were
determined either by a scintillation counting assay (51) or by thin-layer chroma-
tography (30). Luciferase activity was measured by combining 50 to 100 ml of cell
extract with a reaction buffer containing 20 mM HEPES (N-2-hydroxyeth-
ylpiperazine-N9-2-ethanesulfonic acid) (pH 7.9), and 15 mM MgSO4. Light out-
put was measured with an Autolumat LB953 luminometer (Berthold). Protein
was assayed by method of Bradford (16) by using Bio-Rad dye reagent according
to the manufacturer’s instructions.
Electrophoretic mobility shift assay (EMSA) and immunoblotting. COS or
HeLa cells were washed and scraped in PBS and transferred to microcentrifuge
tubes. Cell pellets were resuspended in 100 to 200 ml of lysis buffer (10 mM Tris
[pH 8.0], 60 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol [DTT], 0.1% Nonidet
P-40 [NP-40], 1 mM phenylmethylsulfonyl fluoride [PMSF]) and incubated on
ice for 5 min. The cell membranes were then pelleted by centrifugation (pulsing
for 5 s at 48C), and the cytoplasmic extracts were removed to fresh tubes.
Glycerol was later added to make a 20% solution, and the cytoplasmic extracts
were quick-frozen on dry ice and stored at 2808C until used. The pelleted nuclei
were immediately washed in 1 ml of lysis buffer without NP-40, spun as described
above, and resuspended in 50 ml of buffer C {20 mM HEPES [pH 7.9], 0.75 mM
spermidine, 0.15 mM spermine, 0.2 mM EDTA, 2 mM EGTA [ethylene glycol-
bis(b-aminoethyl ether)-N,N,N9,N9-tetraacetic acid], 2 mMDTT, 20% glycerol, 1
mM PMSF}. NaCl (5 M) was then added to bring the salt concentration to 0.4
M, and the nuclei were extracted on ice for 10 min with occasional vortexing. The
nuclei were then pelleted, and supernatants were collected as nuclear extracts,
quick-frozen on dry ice, and stored at 2808C until used.
EMSA binding reactions were performed by first preincubating 5 to 10 mg of
cell extract with 0.5 to 2 mg of poly(dI-dC) in binding buffer (10 mM Tris [pH
7.7], 50 mMNaCl, 20% glycerol, 1 mMDTT, 0.5 mM EDTA) for 10 min at room
temperature. Approximately 10,000 cpm (0.2 ng) of 32P-labeled DNA probe
encompassing the H-2Kb NF-kB binding site was then added and allowed to bind
for approximately 30 min as described elsewhere (63). The reaction mixture was
then loaded onto native 5% acrylamide TBE (89 mM Tris, 89 mM borate, 2 mM
EDTA) gels.
Polyclonal antipeptide antibodies raised against human NF-kB p65 and human
IkB were obtained from Rockland, Inc. (Boyertown, Pa.). Ab 1141 is a polyclonal
antibody raised against a peptide consisting of amino acids 1 to 14 encoded by
the human p105 gene and was a generous gift of N. Rice (59). Cell extracts were
subjected to sodium dodecyl sulfate–10% polyacrylamide gel electrophoresis
(SDS–10% PAGE) and transferred to nitrocellulose by electroblotting in 25 mM
Tris base–0.2 M glycine–20% methanol at 100 V for 1 h at 48C. The nitrocellu-
lose was probed by using 1:1,000 dilutions of our antibodies and visualized by
using an ECL kit (Amersham) according to the manufacturer’s instructions.
GST fusion protein interaction assay. In vitro-translated 35S-GR protein was
incubated with either DEX (1027 M final concentration) or vehicle for 2 h on ice
and then for 20 min at 258C. The coding regions of NF-kB p50 and p65 were
fused in frame to the glutathione S-transferase (GST) gene by using the pGEX
system (Pharmacia) and grown in BL21 bacteria. A GST/NFY-A fusion construct
transformed into DH5a bacteria was a generous gift from J. Ting, University of
North Carolina. These constructs were grown and harvested according to the
instructions of the manufacturer of the pGEX system (Pharmacia). GST fusion
proteins were purified by binding to glutathione-Sepharose 8A beads (Pharma-
cia) as described elsewhere (74). After equilibration in LBST (20 mM HEPES
[pH 7.9], 100 mM NaCl, 2.5 mM MgCl2, 0.1 mM EDTA, 0.05% NP-40, 1.5%
Triton X-100), 20 ml of the beads was incubated with 5 to 7 ml of activated or
mock-activated 35S-GR and washed as described elsewhere (74). The bound
proteins were eluted by boiling for 5 min in SDS-PAGE loading buffer and
analyzed by SDS-PAGE.
Metabolic labeling and coimmunoprecipitation. COS cells were transfected as
described above and labeled 48 h later. Cultures were washed in PBS and
incubated for 1 h in serum-free medium. The medium was replaced, and 200 mCi
of [35S]Express Label (NEN) per ml was added. Cultures were labeled for 2 h,
and whole-cell extracts were prepared as described elsewhere (63). Extract was
mixed by rotation with 1 ml of the GR-specific antibody, EP57, in the absence or
presence of blocking peptide, for 1 h at 48C; combined with protein A-Sepharose
(PAS) (Sigma); and mixed for 1 h. The PAS pellets were aspirated, washed, and
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boiled in radioimmunoprecipitation (RIP) buffer containing 1% SDS as previ-
ously described (63). Supernatants were collected, diluted to 0.1% SDS with RIP
buffer, and immunoprecipitated overnight with 1 ml of NF-kB subunit antibody
and PAS in the absence or presence of peptide as described elsewhere (63). The
PAS pellets were washed as described above and boiled in SDS loading buffer,
and immunoprecipitates were analyzed by SDS-PAGE and visualized by Phos-
phoImager.
Immunocytochemistry. COS cells were cultured for 24 h in polystyrene two-
chamber slides (Nunc) and transfected as described above but with cell numbers
and reagent amounts proportional to the smaller area. Transfected cells were
washed twice with PBS, solubilized for 1 min in PBS with 0.1% Triton X-100, and
fixed for 45 min in PBS with 3.7% formaldehyde. After three washes in PBS, the
slides were blocked with 10% normal goat serum (Cappel) in PBS plus 2%
bovine serum albumin (BSA). After an additional three washes, the slides were
incubated for 1 h with primary antibody diluted in PBS plus 2% BSA. Antibody
EP57 was raised against a peptide from the human GR and affinity purified as
described elsewhere (20). It was used for our experiments at a dilution of 1:500.
A polyclonal antipeptide antibody raised against human NF-kB p65 was pur-
chased from Santa Cruz Biotechnology and was diluted 1:50 for these experi-
ments. After being washed, the slides were incubated with fluorescein isothio-
cyanate-conjugated secondary antibody (Chemicon) in the dark for 45 min. After
a final wash, a drop of Vectashield (Vector) was added to each chamber area and
a coverslip was applied. The slides were stored at 48C in the dark until visualized
by fluorescence microscopy.
RESULTS
Functional repression of NF-kB p65-mediated transcrip-
tional activation by GR. We began this study by determining
whether GR had any effect on NF-kB p65-mediated gene ex-
pression in transient transfection assays. For these experi-
ments, we transfected expression plasmids encoding p65, GR,
or both into COS cells along with the NF-kB reporter, 3xMHC
CAT. The p65 subunit contributes several strong activation
domains to NF-kB (65). After 48 h, we tested the ability of p65
to transactivate the reporter in the absence or presence of
DEX. When COS cells were transfected with empty expression
vector, a small but easily detectable amount of CAT activity
was measured (Fig. 1A, condition 1). Cotransfection of p65
conferred a three- to fivefold activation over this basal tran-
scription level (Fig. 1A, condition 2). Incubation with DEX
had little effect on this level of activation. GR, when trans-
fected alone, resulted in a level of activity comparable to that
with the vector alone. However, when these cells were treated
with DEX, this activity was reduced (Fig. 1A, condition 3).
Experiments described below show that this reduction is not
due to a general inhibition of basal promoter activity but is due
instead to the inhibition of endogenous NF-kB. When p65 was
cotransfected with GR, we observed an increase in CAT ac-
tivity similar to that seen with p65 alone; however, in this case
the increase was profoundly inhibited by DEX (Fig. 1A, con-
dition 4). Similar results were obtained with a luciferase re-
porter (3xMHCLUC) and by harvesting 16 to 24 h after trans-
fection.
One trivial explanation for this result is that activated GR
inhibits the transcriptional activity of the cytomegalovirus
(CMV) promoter found in the expression plasmids. After co-
transfection of CMVCAT and GR, however, DEX was found
to have no effect on CAT activity (data not shown). Activated
GR’s repression of CAT activity in the absence of cotrans-
fected p65 (Fig. 1A, condition 3) is most likely due to the
presence of endogenous NF-kB activity. Indeed, nuclear ex-
tracts of vector-transfected COS cells contain detectable p65
(Fig. 1C). In addition, with F9 embryonal carcinoma cells,
which contain little detectable basal NF-kB activity, DEX
treatment has no effect on basal transcription of the NF-kB
reporter in GR-transfected cells (data not shown). This DEX-
dependent repression could also be titrated by decreasing the
amount of GR cotransfected with p65, suggesting that the ratio
of GR to p65 determines the level of repression (Fig. 1B).
FIG. 1. Activation of GR inhibits p65 activation of an NF-kB reporter in
transient transfection assays. (A) COS cells were transfected with 12 mg of DNA
including 5 mg of 3xMHCCAT NF-kB reporter construct and either empty
expression vector (vector), 100 ng of pCMV4p65 (p65), 5 mg of pYCGR (GR),
or both (p65 1 GR). Empty expression vector was then added to bring the DNA
content to 12 mg in all cases. DEX was added to the appropriate plates imme-
diately after transfection. Cells were harvested, and extracts were processed for
CAT assays. CAT activity was measured, normalized to input protein levels, and
plotted as the fold change from basal activation (vector). The data represent an
average of four independent experiments. (B) COS cells were transfected as
described for panel A except that the amount of pYCGR expression vector
included varied from 0 to 5 mg, as shown. The data represent an average of two
independent experiments. Data are plotted as described for panel A. (C) West-
ern blot of COS cell nuclear extracts. COS cells were transfected as described for
panel A and harvested after 48 h. NS, nonspecific.
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We then considered the possibility that the activation of GR
might somehow affect transfected nuclear p65 protein levels.
In order to test this, we performed cotransfection assays sim-
ilar to those described above and prepared nuclear extracts for
Western blot (immunoblot) analysis. We found little detect-
able difference in p65 immunoreactivity between untreated
and DEX-treated cultures (Fig. 1C). In addition, this control
was addressed qualitatively by immunocytochemistry (dis-
cussed below). Thus, hormone-activated GR is able to specif-
ically inhibit the ability of the NF-kB p65 subunit to activate
transcription.
AP-1/NF-kB synergy is not inhibited by activated GR. It has
been observed that under some conditions, GR can block AP-
1-mediated transcription, and it has also been observed that
AP-1 can synergize with NF-kB to enhance transcription (24,
68, 74, 82). As COS cells contain detectable levels of AP-1
activity, we considered the possibility that the observed level of
transfected NF-kB activity might be due in part to the presence
of AP-1 and to its physical interaction with NF-kB. GR-medi-
ated repression of NF-kB activity might then be caused by an
interaction between GR and AP-1, thus blocking AP-1/NF-kB
synergy. In order to test this possibility, we utilized F9 cells in
which basal NF-kB and AP-1 activities are much reduced. We
first tested the F9 cells for basal NF-kB and AP-1 transcrip-
tional activity and found that transfection of a reporter con-
struct plus an empty expression vector resulted in virtually
undetectable levels of CAT activity (data not shown). We then
determined whether p65-mediated transactivation is blocked
by activated GR in F9 cells. Cultures were cotransfected with
3xMHCCAT along with constant amounts of GR expression
plasmid and increasing amounts of p65 expression plasmid. As
shown in Fig. 2A, activated GR is able to repress p65-mediated
activation of the reporter in a manner dependent on the ratio
of p65 to GR. As the amount of transfected p65 is increased,
the level of p65 activation of 3xMHCCAT is increased; how-
ever, as shown in Fig. 2A above the bars for each condition, the
ability of GR to repress activation is decreased. Thus, it is clear
that AP-1 activity is not required for GR to inhibit p65 acti-
vation. In addition, as previously shown with COS cells, the
ratio of GR to p65 plays an important role in determining the
extent of this inhibition.
In order to determine if activated GR affects the synergistic
function of NF-kB and AP-1, we initially determined the con-
ditions for GR-mediated repression of AP-1 and AP-1/NF-kB
synergy in our system. As shown in Fig. 2B, a ratio of tran-
scription factors was chosen such that GR blocks p65 activa-
tion by 40 to 50% (Fig. 2A, 200 ng of p65 expression plasmid,
and B, condition 3), GR blocks AP-1 activation by almost 90%
(Fig. 2B, condition 7), and p65 synergizes with AP-1 to in-
crease 3xMHCCAT activity by approximately fourfold (Fig.
2B, compare conditions 2 and 4). DEX treatment of GR-
transfected cultures shows no change in basal activity for either
5xAP-1CAT (Fig. 2B, condition 6) or 3xMHCCAT (data not
shown). We then compared the effect of activated GR on
p65-mediated transcription with the effect of activated GR on
p65/AP-1-mediated transcription. Surprisingly, the NF-kB/
AP-1 synergistic activity is resistant to glucocorticoid-mediated
repression (Fig. 2B, compare conditions 4 and 5), despite the
fact that GR represses the two transcription factors separately.
Thus, AP-1 seems to protect p65 from the repression mediated
by activated GR and further shows that GR does not indis-
criminately inhibit transcription factor activity.
Physical association of GR and NF-kB subunits. The pre-
vious data persuaded us to determine if GR directly associates
with NF-kB subunits. One possible effect of a physical inter-
action between the two transcription factors would be the
inhibition of GR-mediated transactivation. In order to test
this, we cotransfected COS cells with a GRECAT reporter in
the presence of a constant amount of GR and an increasing
amount of p65. GR, when activated, induces a 17-fold increase
in reporter gene transcription over the basal activity level (Fig.
3). As an increasing amount of p65 is cotransfected with GR,
this activity is decreased to a mere twofold activation in the
presence of 2.5 mg of p65 expression plasmid. Thus, when
cotransfected, p65 and GR repress each other’s ability to trans-
activate in a manner dependent on the ratio of the two pro-
FIG. 2. AP-1/NF-kB synergy is not inhibited by GR in transient transfection assays. F9 cells were transfected with 12 mg of DNA. DEX was added to appropriate
plates immediately after transfection. Cells were harvested 16 h after transfection. Data were normalized and plotted as described in the legend to Fig. 1. (A) Each
transfection mixture contained 5 mg of 3xMHCCAT NF-kB reporter construct and 5 mg of pYCGR. A variable amount of pCMV4p65 DNA, from 0 to 200 ng, was
transfected as shown. Empty expression vector was added to bring all samples to 12 mg of DNA. Numbers shown above the bars for each condition represent the ratio
of the transcriptional activation of untreated to DEX-treated samples. (B) F9 cells were transfected with combinations of fos and jun (AP-1), p65, or GR expression
plasmids (as indicated below the bars) along with either 5 mg of 3xMHCCAT reporter (conditions 1 to 5) or 5xAP-1CAT reporter (conditions 6 and 7). The amounts
of expression plasmids transfected were as follows: p65, 200 ng; GR, 5 mg; fos and jun (AP-1), 500 ng each. Empty expression vector was added to all samples to bring
the DNA content to 12 mg. Data are representative of two independent experiments. h, DEX treatment; ■, no DEX treatment.
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teins. This symmetry lends further credence to the hypothesis
that p65 and GR physically interact.
In order to test whether NF-kB subunits are capable of
physically interacting with GR, we generated bacterial GST
fusion proteins containing either NF-kB p50, NF-kB p65, or
NFY-A (a DNA-binding protein which interacts with MHC
class II regulatory elements) and bound them to glutathione-
Sepharose beads. In vitro-translated 35S-GR was prepared and
then activated by incubation with DEX. After the beads had
been washed extensively, binding reactions with either acti-
vated GR or mock-activated GR were set up. The beads were
again washed extensively and boiled in loading buffer, and
remaining 35S-GR was analyzed by SDS-PAGE. As shown in
Fig. 4A, 35S-GR bound specifically to GSTp50 and GSTp65
but not to GSTpNFY-A or GST alone. Interestingly, mock-
activated 35S-GR bound NF-kB subunits as well as DEX-acti-
vated 35S-GR did. The implications of this finding are dis-
cussed below.
We then extended this observation by attempting to coim-
munoprecipitate transfected NF-kB subunits associated with
GR using anti-GR antisera. COS cells were cotransfected with
GR and p50 or with GR and p65. Cultures were then labeled
with [35S]methionine, and whole-cell extracts were prepared.
These extracts were then incubated with GR-specific antisera,
and GR-containing complexes were precipitated with protein
A-Sepharose, washed extensively as described in Materials and
Methods, and analyzed by SDS-PAGE. While labeled GR was
specifically immunoprecipitated, high background levels pre-
cluded visualization of cotransfected NF-kB subunits (data not
shown). In order to decrease background, these precipitates
were then boiled in RIP buffer containing 1% SDS, diluted to
0.1% SDS, and reprecipitated with antiserum specific for p65
or p50, respectively. The results are shown in Fig. 4B. With
COS cells cotransfected with p50 and GR, p50 is clearly
present in GR-containing immunoprecipitates. The specificity
of this interaction can be determined by inclusion of the p50
peptide (Fig. 4B, left panel). Similarly, with COS cells cotrans-
fected with p65 and GR, p65 is clearly present (Fig. 4B, right
panel). In addition, both signals can be blocked by incubation
with GR peptide in the first immunoprecipitation step (data
not shown). Interestingly, DEX treatment is apparently not
necessary for this interaction, consistent with our GST data
(see Discussion). Thus, GR is capable of physically interacting
with NF-kB subunits both in vitro and in vivo.
GR block NF-kB DNA binding in the presence of DEX. To
further characterize the mechanism of glucocorticoid-medi-
ated repression of p65 activity, we analyzed the effect of acti-
vated GR on NF-kB subunit DNA binding. COS cells were
cotransfected with the GR expression plasmid plus an expres-
sion plasmid encoding either p65, p50, or c-rel and were cul-
tured in the presence or absence of DEX. After 3 days, the
cells were harvested and extracts were prepared for Western
FIG. 3. p65 inhibits GR activation of a GR reporter in transient transfec-
tions. COS cells were transfected with 12 mg of DNA. Each transfection mixture
contained 5 mg of GRECAT reporter plasmid and 5 mg of pYCGR expression
plasmid. Increasing amounts of pCMV4p65 expression plasmid from 0 to 2.5 mg
were included as shown. DEX was added immediately after transfection. Data
were normalized and plotted as described in the legend to Fig. 1 and are
representative of two independent experiments. h, DEX treatment; ■, no DEX
treatment.
FIG. 4. NF-kB subunits can physically interact with in vitro-translated GR.
(A) In vitro-translated 35S-GR was incubated with DEX (1) or vehicle (2) as
described in Materials and Methods. GST fusion proteins were grown, extracted
from bacteria, and bound to glutathione-Sepharose beads as described in Ma-
terials and Methods. Beads bound to GST fusion constructs containing p50, p65,
NFY-A, or GST alone were then incubated with activated or mock-activated
35S-GR as described in Materials and Methods. The beads were washed, boiled
in SDS-PAGE loading buffer, and size separated by SDS-PAGE. 35S-GR was
visualized with a PhosphoImager. (B) COS cells were cotransfected with 1.25 mg
of pYCGR (GR) in combination with 1.25 mg of p50 (left panel) or with 1.25 mg
of p65 (right panel). Cultures were labeled with [35S]methionine, whole-cell
extracts were prepared, and GR-containing complexes were immunoprecipitated
as described in Materials and Methods. Washed PAS pellets were boiled in
SDS, and diluted supernatants were reimmunoprecipitated with antibody spe-
cific for p50 (left panel) or p65 (right panel) in the absence (2) or presence (1)
of blocking peptide. Numbers on the left indicate molecular mass (in kilodal-
tons).
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blot analysis and EMSA. Figure 5 shows a series of represen-
tative experiments. Quantitative Western blots were per-
formed by titrating the untreated extract against the DEX-
treated extract in order to ensure that equal amounts of NF-kB
subunit protein were present in DEX-treated and untreated
EMSA binding reaction mixtures (Fig. 5, WEST). With EMSA
analysis, we found that DEX treatment caused a marked re-
duction in the ability of the NF-kB/Rel subunits to bind DNA
despite the presence of equal amounts of NF-kB subunit pro-
tein in the EMSA DNA-binding reaction mixtures (Fig. 5,
EMSA). Interestingly, in COS cells after 72 h, cotransfection
of GR caused a significant reduction of transfected p65 but not
transfected p50 or c-rel subunits as measured by Western blots
(data not shown). We will return to this observation in a sub-
sequent section.
Analysis of the subcellular localization of GR and p65 fol-
lowing cotransfection. In order to directly visualize the distri-
bution of proteins in the absence or the presence of DEX, we
utilized GR and p65 cotransfection followed by immunocyto-
chemistry. Shown in Fig. 6a through c are cotransfected cells
stained with antibodies against p65. Cells stained with antibod-
ies against GR are shown in Fig. 6d through f. In untreated
transfected cells, p65 staining is both nuclear and cytoplasmic
(Fig. 6a, brightly stained cells). The presence of p65 in the
cytoplasm is likely due to the fact that p65 transfection leads to
an increase in COS IkB protein, which stabilizes cytoplasmic
p65. Interestingly, as seen before (12), the distribution of p65
in the nucleus is punctate. One can also see specific staining of
endogenous NF-kB in nontransfected cells, primarily in the
cytoplasmic and perinuclear regions (Fig. 6a, weakly stained
cells). DEX treatment has little effect on the localization of
transfected p65 (Fig. 6b). In untreated transfected cells, GR
staining is primarily cytoplasmic (Fig. 6d, brightly stained
cells). In the presence of DEX, however, GR is entirely nuclear
(Fig. 6e). Fig. 6c and f show the staining by peptide-blocked
antibodies, thus illustrating the level of background staining for
these experiments. In addition, we found that the distribution
of cotransfected p65 and GR was identical to that of p65 or GR
transfected alone (data not shown). Thus, under conditions in
which GR transactivation is inhibited almost 10-fold by the
cotransfection of p65 (Fig. 3, rightmost bars), the GR/NF-kB
FIG. 5. Activation of GR blocks NF-kB subunit DNA binding. COS cells
were transfected with 5 mg of pYCGR plus either 200 ng of pCMV4p50 (left
panel), 200 ng of pCMV4p65 (middle panel), or 200 ng of pCMV4rel (right
panel). Cultures were either treated with DEX immediately after transfection
(1) or left untreated (2), as shown at the top of the figure. Nuclear extracts were
prepared for EMSA and Western blot analysis. Each upper panel shows a
representative EMSA using the MHC class I H-2Kb NF-kB binding site as a
DNA probe (EMSA). Gels were analyzed with a PhosphoImager. Below each
EMSA panel, a Western blot probed with the appropriate NF-kB subunit-
specific antisera is shown (WEST). In the p50 Western blot, the top band
corresponds to transfected p50. The middle band is nonspecific (NS), and the
lower band corresponds to endogenous p50.
FIG. 6. Immunocytochemical analysis of transfected p65 and GR. COS cells were transfected with equal amounts of p65 and GR expression plasmid, cultured for
24 h in the absence or presence of DEX, and processed for immunocytochemistry as described in Materials and Methods. (a) Untreated cells stained for p65. (b)
DEX-treated cells stained for p65. (c) Peptide-blocked p65 staining. (d) Untreated cells stained for GR. (e) DEX-treated cells stained for GR. (f) Peptide-blocked GR
staining.
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subunit complex is not sequestered as detected by immunocy-
tochemistry (Fig. 6b and e).
Glucocorticoids block activation of endogenous NF-kB ac-
tivity. In order to determine whether endogenous NF-kB could
be repressed by glucocorticoids through the activation of en-
dogenous GR, HeLa cells were pretreated with DEX for 16 h
and then treated with TNF-a for 1 h to activate endogenous
NF-kB. Nuclear extracts were prepared and analyzed by West-
ern blot and EMSA. We first observed that DEX treatment
resulted in a reproducible and significant reduction in TNF-
inducible nuclear p65 subunits but not p50 subunits (as de-
scribed above for transfected COS cells after 72 h). We under-
took to more accurately measure the difference in p65 protein
levels both to understand the extent of loss of nuclear p65
in DEX-treated cells and to be able to perform EMSA analy-
sis on nuclear extracts containing comparable amounts of
p65 protein. Nuclear extracts from DEX- and TNF-a-treated
cultures were run next to decreasing amounts of extracts
from TNF-a-treated cultures and analyzed by Western blot-
ting. A representative experiment is shown in Fig. 7A. The
autoradiograms were scanned, and the quantitated bands
from the TNF-a-treated cultures were used to construct a
standard curve against which the extract from DEX-treated
cultures could be compared. In the presence of DEX, nuclear
p65 was measured as 0.62 (60.19) of that found in the absence
of DEX (average of three experiments). We also measured
the amount of p50 in nuclear extracts and found it to be
unchanged (Fig. 7A, bottom panel). In order to determine if
the loss of nuclear p65 was paralleled by a gain of cytoplas-
mic p65, we also analyzed matched cytoplasmic extracts by
Western blotting and found that DEX treatment resulted
in a slight but reproducible increase in cytoplasmic p65 (Fig.
7A). For cytoplasmic extracts, the presence of DEX resulted
in an average increase of 1.14 6 0.19 for p65 in comparison
with the amount in untreated cultures. In addition, we ob-
served a correlation between the degree of loss of nuclear
p65 and the degree of gain of cytoplasmic p65 in these exper-
iments. Figure 7B shows an EMSA analysis of a representative
experiment in which nuclear extracts containing similar
amounts of p65 protein were compared (lanes 2 and 3). TNF
treatment induced the translocation of NF-kB to the nucleus
(Fig. 7B, lane 2). Pretreatment with DEX resulted in a pro-
found loss of TNF-a-induced NF-kB as well as p50 homodimer
(KBF1) gel shift activity (Fig. 7B, lane 3). Similar data were
obtained by treating cells with IL-1 (data not shown). Small
amounts of constitutive nuclear NF-kB can be visualized by
EMSA with long film exposures. DEX treatment also blocks
the ability of this constitutive NF-kB to bind the DNA probe
(data not shown). Thus, we have observed that in HeLa
cells, GR inhibits NF-kB both by blocking nuclear NF-kB
binding to DNA and by generally decreasing NF-kB p65 nu-
clear protein levels, possibly by sequestering p65 in the cyto-
plasm.
In order to determine if DEX treatment results in a func-
tional loss of NF-kB activity, HeLa cells were transfected with
the NF-kB reporter, 3xMHCCAT, and treated with DEX 4 to
FIG. 7. DEX inhibits the activation of endogenous NF-kB in response to
TNF-a. HeLa cells were treated with DEX and TNF-a as described in Materials
and Methods. Nuclear and cytoplasmic extracts were then prepared for Western
blot and EMSA or CAT assay. (A) Western blot analysis of nuclear and cyto-
plasmic extracts for p65 and p50 subunit immunoreactivity. For nuclear p65, 42.4
mg of TNF-plus-DEX-treated cell extract (1) was compared with dilutions of
TNF-treated cell extract (2) corresponding to 20.8, 10.4, and 4.16 mg, respec-
tively. For cytoplasmic p65, 2.0 mg of TNF-plus-DEX-treated cell extract (1) and
TNF-treated extracts (2) were compared. For nuclear p50, 50.0 mg of TNF-plus-
DEX-treated cell extract and TNF-treated extracts were compared. (B) EMSA
analysis of HeLa nuclear extracts. Extracts from TNF-a-treated cells containing
equal amounts of p65 protein as measured by Western blot were compared. Lane
1, control, 11.4 mg; lane 2, TNF-a treated, 11.4 mg; lane 3, DEX-plus-TNF-a
treated, 14.5 mg. F, free probe. (C) HeLa cells were transfected with 10 mg of
3xMHCCAT reporter construct (left and middle) or 10 mg of GRECAT (right).
At 4 h posttransfection, appropriate plates were treated with DEX or left un-
treated (2) as shown at the top of the figure. At 24 h posttransfection, appro-
priate plates were treated with TNF-a (left panel) or IL-1 (middle panel) or left
untreated (2). The cells were harvested 48 h posttransfection. Results of rep-
resentative CAT assays are shown. The percent conversion of [14C]chloram-
phenicol was measured by using a PhosphoImager and is shown at the bottom of
the figure. Data are representative of three independent experiments.
VOL. 15, 1995 GLUCOCORTICOID REPRESSION OF NF-kB 949
6 h posttransfection. After 20 h, cultures were treated with
either TNF-a or IL-1. Cells were harvested 24 h later. Repre-
sentative experiments are shown in Fig. 7C. TNF-a and IL-1
both produced a 5- to 10-fold induction in CAT activity in
these experiments. Pretreatment with DEX resulted in a sig-
nificant reduction in CAT activity. Thus, endogenous HeLa
GR is capable of repressing endogenous NF-kB activity. As a
control to show that DEX did not block gene expression non-
specifically, HeLa cells were also transfected with the GR
reporter, GRECAT. DEX treatment resulted in a 40-fold ac-
tivation of GRECAT over basal transcription levels. HeLa
cells contain numerous forms of TNF-a-inducible NF-kB-like
complexes (10). It is possible that while the transfected NF-kB
subunits are rendered unable to bind DNA (Fig. 5), certain
endogenous NF-kB subunit dimers might be resistant to GR-
mediated repression. This and other possible mechanisms
which might contribute to the remaining NF-kB-like activity
present after DEX treatment are discussed below. In any
event, it is clear that endogenous NF-kB activity, induced by a
physiological signal, can be significantly repressed by glucocor-
ticoids.
Effect of the antisteroid RU486 on the inhibition of p65
activity. In order to begin to dissect the features of GR which
are necessary for the inhibition of NF-kB, we studied the effect
of the antisteroid RU486 in our COS cell transfections. In the
presence of RU486, GR is able to dissociate from HSP90 and
translocate to the nucleus; however, its ability to transactivate
is markedly reduced (13). GR and p65 were cotransfected as
described above, and the cells were cultured in the presence of
either 1027 M DEX, 1026 M RU486, or both. Interestingly, we
found that RU486 alone was able to partially inhibit p65 ac-
tivity (Fig. 8A). While DEX alone was able once again to block
p65 activation, in the presence of a 10-fold excess of RU486,
p65 activity was partially inhibited to an extent similar to that
seen with RU486 alone, consistent with the role of RU486 as
a competitive inhibitor of GR (Fig. 8A). Thus, GR-mediated
transcription does not seem to be required for the inhibition of
p65, consistent with our data suggesting that a physical asso-
ciation between GR and NF-kB is in part responsible for the
inhibition of NF-kB.
Analysis of GR transactivation mutants. In order to further
test the hypothesis that GR-mediated transactivation is not
required for the inhibition of NF-kB, we tested several GR
transactivation mutants. Figure 8B shows the structure of the
GR and the two mutants analyzed. D428/490GR has a deletion
in the zinc finger region. This protein can dimerize and trans-
locate to the nucleus but cannot bind DNA (19). In contrast to
wild-type GR, D428/490GR had no effect on p65 activation
when cotransfected with p65 into COS cells and activated by
DEX (Fig. 8B). Interestingly, this zinc finger region has been
shown to be required for the physical association of GR and
AP-1 (35, 40, 46, 68, 82). Thus, this mutation may have mul-
tiple effects on the properties of GR. A second transactivation
mutant, D77/262GR, has a deletion in the N-terminal transac-
FIG. 8. Effects of RU486 and GR transactivation mutants on p65 inhibition. COS cells were transfected with 12 mg of DNA including 5 mg of 3xMHCLUC NF-kB
reporter construct along with p65 and either wild-type GR or mutant GR as described in the legend to Fig. 1. (A) COS cells transfected with p65 plus GR were either
left untreated (control), or treated with 1026 M RU486 (RU486), 1027 M DEX (DEX), or both (RU4861DEX) for 24 h, after which the cells were harvested for
luciferase assays. Numbers on the left indicate fold activation. (B) At the top is a diagram of wild-type GR and GR transactivation mutants. Shaded rectangles represent
domains of GR. TD, transactivation domain Tau 1; DNA, DNA-binding domain containing two zinc finger motifs; STEROID, steroid-binding domain. At the bottom,
results are shown for an experiment in which COS cells were transfected with p65 and either D77/262GR or D428/490GR and were cultured in the absence (■) or
presence (h) of 1027 M DEX for 24 h.
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tivation domain resulting in a 10- to 20-fold drop in transacti-
vation of a GRE. When D77/262GR was cotransfected with
p65 into COS cells, DEX activation resulted in a significant
inhibition of p65 activity (Fig. 8B). Both mutant proteins were
expressed at levels similar to those of wild-type GR as mea-
sured by Western blot (data not shown). We interpret these
data as showing that the transactivating potential of GR cannot
fully account for the inhibition of NF-kB activity. In addition,
we have found that a region encompassing the zinc finger is
required for inhibition of NF-kB function.
DISCUSSION
Cross-coupling of GR and NF-kB. In this study, we have
shown that NF-kB, an important regulator of immune system
and inflammation genes, is inhibited by glucocorticoid admin-
istration, in part through cross-coupling with the GR and in
part by a loss of nuclear NF-kB subunit protein (discussed
below). Our current understanding of NF-kB suggests that
GR-mediated repression of inducible NF-kB activity might
play an important role in mediating the repression of cytokine
transcription. Cross-coupling is suggested by the symmetrical
nature of the mutual inhibition of p65 and GR (Fig. 1 and 3),
by the ability of GST/NF-kB fusion proteins to bind in vitro-
translated GR (Fig. 4A), by the ability to coimmunoprecipitate
GR and NF-kB subunit proteins (Fig. 4B), and by the ability to
uncouple GR-mediated transcription and inhibition of p65
(Fig. 1B and 8B). In addition, we have shown that DEX treat-
ment causes the loss of NF-kB DNA binding to the H-2Kb
region I enhancer, a strong NF-kB-responsive element (Fig.
7B).
The interaction of NF-kB and GR is similar to the interac-
tion between AP-1 and GR. In both cases, a mutual repression
is observed. Numerous studies have identified the zinc finger
region of GR as a critical domain for the physical interaction
with and repression of AP-1 (35, 40, 46, 68, 82). We have found
that the zinc finger region is required for repression of p65
activity (Fig. 8B). Interestingly, the relationship between GR
and these two transcription factor families is complicated by
the ability of NF-kB/AP-1 synergistic complexes to overcome
glucocorticoid-mediated repression (Fig. 2B). These complex
interactions potentially add an additional level of regulation to
this system.
DEX-mediated loss of nuclear p65. We have shown that
when HeLa cells are cultured in the presence of DEX, the level
of nuclear p65 protein present after TNF-a induction is de-
creased. Two hypotheses explaining the loss of p65 include
protein destabilization and cytoplasmic sequestration. While
we have no evidence for DEX inducing an increase in the
degradation of p65, we cannot discount this possibility. We
have, however, observed a slight increase in the amount of
cytoplasmic p65, suggesting that DEX may increase the
amount of p65 being sequestered in the cytoplasm, although
we have shown by immunocytochemistry that the GR/NF-kB
complex itself is not cytoplasmically sequestered in the pres-
ence of DEX (Fig. 6). Molecules which do sequester NF-kB in
the cytoplasm have been well characterized and include the
IkB family members IkBa (5, 12) and IkBb (34), as well as the
NF-kB precursors p105 (48, 59) and p100 (63). The mecha-
nisms regulating the level of these sequestering agents are
complex. NF-kB itself can induce some of these components,
such as IkBa and p105, at the level of transcription (18, 21, 42,
78). In addition, NF-kB can stabilize the rapidly degraded
IkBa through physical association. It is intriguing to speculate
whether GR induces the transcription of any of these seques-
tering components.
The role of GR-mediated transactivation in the inhibition of
NF-kB. We observed a partial inhibition of p65 activity both
with RU486 in complex with wild-type GR and with the GR
transactivation mutant, D77-262. One possible interpretation
of these data is that the conformation of (mutant or RU486-
bound) GR is compromised such that its ability to interact with
p65 is decreased. Alternatively, it may be that there exists a
transcriptional component to the GR-mediated inhibition
which is necessary for full repression of NF-kB. Further ex-
perimentation will be required to distinguish between these
possibilities.
DEX dependence of the GR-mediated inhibition of NF-kB.
The data shown in Fig. 4 suggest that glucocorticoids are not
required for GR interaction with NF-kB. If so, why is GR-
mediated repression of NF-kB glucocorticoid dependent? The
binding of hormone to the receptor induces a conformational
change allowing GR to dissociate from HSP90 and translocate
to the nucleus. It has been demonstrated that upon dissocia-
tion, a large pool of GR cycles between the nucleus and the
cytoplasm (55). Our model would predict that this cycling
hormone-GR complex is then competent to interact with re-
leased NF-kB. Alternatively, hormone binding may be re-
quired in vivo both for dissociation from HSP90 and for GR
association with NF-kB. Perhaps in vitro-synthesized GR folds
into a more permissive conformation, allowing DEX-indepen-
dent association with NF-kB subunits.
Several physiological consequences of DEX administration
can be explained by repression of NF-kB activity. Within 4 to
6 h after a single glucocorticoid dose, the human immune
system undergoes a striking transformation. Monocyte as well
as B- and T-lymphocyte populations redistribute from the
blood to other lymphoid compartments, possibly the bone mar-
row, while the circulating neutrophil populations increase (23).
Primary cells derived from these patients are unresponsive to
mitogenic or antigenic stimulation in mixed lymphocyte reac-
tions (23, 57). In addition, glucocorticoid treatment blocks
monocyte secretion of IL-1 or IL-6 and T-cell secretion of IL-2,
as well as blocking lymphocyte secretion of IL-3, gamma in-
terferon, and GM-CSF (22, 23, 79).
Cytokines such as IL-1, IL-6, TNF-a, and GM-CSF can
function in a number of ways to activate and amplify immune
and inflammation responses. Cytokine secretion requires de
novo cytokine gene transcription. Studies of the IL-1 and IL-6
promoters have shown that NF-kB regulatory elements play an
important role in the induction of transcription (33, 45, 72, 83).
IL-2 secretion is a required autocrine signal for quiescent T
cells to enter the cell cycle as they progress to the activated
state. Studies of the progression of cytotoxic T-lymphocyte
clones or BALB/c 3T3 fibroblasts from quiescence to the cell
cycle have correlated this progression with a rapid and tran-
sient induction of NF-kB activity (8, 79). The IL-2 promoter
also contains an NF-kB site within the context of a tandem
array of transcription factor binding sites which include NF-
AT, NF-kB, AP-1, and Oct-1 (71, 79). Thus, a glucocorticoid-
mediated block of NF-kB activity may function to repress the
immune response at multiple levels through blocking of cyto-
kine transcription.
Glucocorticoids have been shown to inhibit lymphocyte mi-
gration in vitro, presumably by altering their adherence prop-
erties (23). It has been hypothesized that the glucocorticoid-
mediated redistribution of lymphocytes involves changes in cell
surface properties regulating cell adhesion. Interestingly,
NF-kB has been recently implicated in the regulation of en-
dothelial cell adhesion molecules such as I-CAM, V-CAM, and
E-selectin (37, 50). These adhesion molecules must be ex-
pressed by vascular endothelium in order to allow leukocyte
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extravasation. Thus, repression of NF-kB would be expected to
block leukocyte infiltration associated with inflammation.
While our manuscript was in preparation, two reports spe-
cifically implicating NF-kB in the DEX-mediated inhibition of
two cytokine promoters were published. The first showed that
an NF-kB-responsive element in the IL-6 promoter was nec-
essary for DEX-mediated inhibition of IL-1 induction of this
gene (58). The second report described a similar study using
the IL-8 promoter (49). In both studies, DEX treatment
caused a loss of NF-kB binding to its respective DNA-binding
site. Our work shows similar results. In addition, our work
shows that p50 (Fig. 4 and 5) and likely c-rel (Fig. 5) directly
interact with GR. We have extended these observations by
showing that GR interacts with endogenous NF-kB subunits to
block DNA binding. Interestingly, DEX treatment causes a
decrease in nuclear levels of p65, thus illustrating a novel
mechanism for GR-mediated inhibition of NF-kB activity. We
have shown that as with AP-1/GR interactions, the zinc finger
domain is critical for inhibition of NF-kB. In addition, we show
that under conditions in which AP-1 and NF-kB can synergize,
GR is unable to repress NF-kB activity. Finally, we demon-
strate that GR-mediated transcription may be uncoupled from
the inhibition of NF-kB.
The discovery of cross-coupling between transcription factor
families has altered our perceptions of how transcription is
regulated. Interactions between transcription factors and their
DNA-binding sites can be modulated, enhanced, or blocked by
interactions with other transcription factors. Cross-coupling
can result in transcriptional synergy, as seen with NF-kB/bZIP
family member complexes, or transcriptional repression, as
seen with AP-1/GR or NF-kB/GR complexes. We have dis-
cussed the interaction between GR and NF-kB in terms of its
pharmacological implications. It will be important to deter-
mine whether other steroid hormone receptors interact with
NF-kB and to determine the physiological and potential de-
velopmental consequences of this interaction.
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